FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:181-183 January 8, 2004 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Raghu, G. PubMed Citation

Idiopathic pulmonary fibrosis, defined pathologically as usual interstitial pneumonia, is a fatal disease that occurs most commonly among persons who are 60 years of age or older and in otherwise good health. Usual interstitial pneumonia progressively impairs breathing, but because its onset is insidious, patients are frequently treated for other diseases for many months. By the time the diagnosis is established, pulmonary function has often substantially deteriorated.¹

Several entities fall under the wide umbrella of chronic interstitial pneumonias,² including usual interstitial pneumonia, nonspecific interstitial pneumonitis, desquamative interstitial pneumonia, acute interstitial pneumonia, respiratory bronchiolitis–associated interstitial lung disease, and cryptogenic organizing pneumonia.³ . . . [Full Text of this Article]

Source Information

From the Division of Pulmonary and Critical Care Medicine, Mount Sinai Medical Center, New York.

Related Letters:

Interferon Gamma-1b for Pulmonary Fibrosis
Hill A. R., Fruchter O., Eisner M. D., Tsoutsou P. G., Gourgoulianis K. I., Vourlekis J. S., Richeldi L., Raghu G., King T. E. Jr., Teirstein A. S.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:1794-1797, Apr 22, 2004. Correspondence

This article has been cited by other articles:

• Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., Fatenejad, S. (2008). Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial. Am. J. Respir. Crit. Care Med. 178: 948-955 [Abstract] [Full Text]  
• Raghu, G., Yang, S. T.-Y., Spada, C., Hayes, J., Pellegrini, C. A. (2006). Sole Treatment of Acid Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis: A Case Series. Chest 129: 794-800 [Abstract] [Full Text]  
• Bajwa, E. K., Ayas, N. T., Schulzer, M., Mak, E., Ryu, J. H., Malhotra, A. (2005). Interferon-{gamma}1b Therapy in Idiopathic Pulmonary Fibrosis: A Metaanalysis. Chest 128: 203-206 [Abstract] [Full Text]  
• Lee, H.-L., Ryu, J. H., Wittmer, M. H., Hartman, T. E., Lymp, J. F., Tazelaar, H. D., Limper, A. H. (2005). Familial Idiopathic Pulmonary Fibrosis: Clinical Features and Outcome. Chest 127: 2034-2041 [Abstract] [Full Text]  
• Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., Sato, A., Kudoh, S., for the members of the Research Group for Diffuse, (2005). Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 171: 1040-1047 [Abstract] [Full Text]  
• Hill, A. R., Fruchter, O., Eisner, M. D., Tsoutsou, P. G., Gourgoulianis, K. I., Vourlekis, J. S., Richeldi, L., Raghu, G., King, T. E. Jr., Teirstein, A. S. (2004). Interferon Gamma-1b for Pulmonary Fibrosis. NEJM 350: 1794-1797 [Full Text]